Authorizes use of healthcare platforms providing discounted prices for payment of prescription and non-prescription drugs or devices and for telehealth and telemedicine services.
Impact
The bill can significantly impact state laws governing pharmacy practices and the utilization of telehealth services. By recognizing and formalizing the role of healthcare platforms in offering discounted medications, A3669 promotes greater access to affordable healthcare options for the public. This legislation might streamline processes within pharmacies and potentially enhance competition among drug pricing. Furthermore, it allows pharmacists to help patients find lower-cost alternatives and supports the continued dialogue about transparency in drug pricing.
Summary
Assembly Bill A3669 seeks to authorize the use of healthcare platforms such as GoodRx and SingleCare for patients to obtain discounted prices for prescription and non-prescription drugs. This new regulation integrates these healthcare platforms into the legal framework of pharmacy benefits managers and telehealth services, allowing patients to apply their membership accounts for payments. The bill emphasizes that network pharmacies should not be penalized for accepting discounts that these platforms provide, which may benefit patients with or without health insurance coverage.
Contention
Notable points of contention surrounding Bill A3669 may involve the operational implications for pharmacy benefits managers. The legislation prohibits these managers from imposing penalties on pharmacies for accepting lower prices from healthcare platforms. This could lead to resistance from pharmaceutical companies and benefits administrators who might view such measures as undermining their pricing structures. Additionally, the bill will require robust communication and transparency to ensure that patients are fully informed about their choices between insurance coverage and platform discounts.
Carry Over
Authorizes use of healthcare platforms providing discounted prices for payment of prescription and non-prescription drugs or devices and for telehealth and telemedicine services.
Revises telehealth and telemedicine requirements concerning adult prescription of certain Schedule II drugs for treatment of attention-deficit/hyperactivity disorder.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.